Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice

Ann Oncol. 2019 Nov 1;30(11):1691-1694. doi: 10.1093/annonc/mdz392.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / genetics*
  • Clinical Trials as Topic
  • Genetic Testing / economics
  • Genetic Testing / trends*
  • Humans
  • Medical Oncology / economics
  • Medical Oncology / methods
  • Medical Oncology / trends*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Patient Selection
  • Precision Medicine / economics
  • Precision Medicine / methods*
  • Precision Medicine / trends
  • Reimbursement Mechanisms
  • State Medicine / economics
  • United Kingdom

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor